{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T00:35:18Z","timestamp":1793061318348,"version":"4.5.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"US Department of Defense","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.xcrm.2026.102934","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T14:43:01Z","timestamp":1784904181000},"page":"102934","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Combine antibody-drug conjugate with cmLumiOpto for triple-negative breast cancer treatment"],"prefix":"10.1016","volume":"7","author":[{"given":"Tanvi","family":"Varadkar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuoxin \u201cZora\u201d","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingnan","family":"Si","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiashuai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhantao","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjana Gautam","family":"Khanal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srijita","family":"Chowdhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandini","family":"Tsaliki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lufang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4617-9750","authenticated-orcid":false,"given":"Xiaoguang \u201cMargaret\u201d","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2026.102934_bib1","first-page":"647","article-title":"Research Progress on Molecular Subtyping and Modern Treatment of Triple-Negative Breast Cancer","volume":"15","author":"Tong","year":"2023","journal-title":"Breast Cancer"},{"key":"10.1016\/j.xcrm.2026.102934_bib2","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13058-020-01296-5","article-title":"Triple-negative breast cancer molecular subtyping and treatment progress","volume":"22","author":"Yin","year":"2020","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102934_bib3","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1007\/s12032-024-02456-9","article-title":"The treatment landscape of triple-negative breast cancer","volume":"41","author":"Hu","year":"2024","journal-title":"Med. Oncol."},{"key":"10.1016\/j.xcrm.2026.102934_bib4","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-071674","article-title":"Advances in systemic therapies for triple negative breast cancer","volume":"381","author":"Leon-Ferre","year":"2023","journal-title":"Br. Med. J."},{"key":"10.1016\/j.xcrm.2026.102934_bib5","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.cell.2018.03.041","article-title":"Chemoresistance Evolution in Triple-Negative Breast Cancer Delineated by Single-Cell Sequencing","volume":"173","author":"Kim","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2026.102934_bib6","doi-asserted-by":"crossref","DOI":"10.3390\/cells8090957","article-title":"Mechanisms of Chemotherapy Resistance in Triple-Negative Breast Cancer-How We Can Rise to the Challenge","volume":"8","author":"Nedeljkovi\u0107","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.xcrm.2026.102934_bib7","article-title":"Antibody-drug conjugates: Current challenges and innovative solutions for precision cancer therapy","volume":"6","author":"Zhou","year":"2025","journal-title":"M\u00e9d. Sur"},{"key":"10.1016\/j.xcrm.2026.102934_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16203517","article-title":"Targeted Therapy in Breast Cancer: Advantages and Advancements of Antibody-Drug Conjugates, a Type of Chemo-Biologic Hybrid Drugs","volume":"16","author":"Mukherjee","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.xcrm.2026.102934_bib9","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17060958","article-title":"Opportunities and Challenges in Antibody-Drug Conjugates for Cancer Therapy: A New Era for Cancer Treatment","volume":"17","author":"Buyukgolcigezli","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.xcrm.2026.102934_bib10","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1177\/1078155220951862","article-title":"The role of ado-trastuzumab emtansine in current clinical practice","volume":"27","author":"Turshudzhyan","year":"2021","journal-title":"J. Oncol. Pharm. Pract."},{"key":"10.1016\/j.xcrm.2026.102934_bib11","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1186\/s12913-025-12876-6","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine for human epidermal growth factor receptor 2 positive metastatic breast cancer: cost-effectiveness analysis from Iranian experience","volume":"25","author":"Yaghoubi","year":"2025","journal-title":"BMC Health Serv. Res."},{"key":"10.1016\/j.xcrm.2026.102934_bib12","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.breast.2022.10.007","article-title":"Antibody-drug conjugates targeting TROP-2: Clinical development in metastatic breast cancer","volume":"66","author":"Shastry","year":"2022","journal-title":"Breast"},{"key":"10.1016\/j.xcrm.2026.102934_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1447280","article-title":"Sacituzumab govitecan in triple-negative breast cancer: from bench to bedside, and back","volume":"15","author":"Rossi","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xcrm.2026.102934_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2025.104589","article-title":"FDA and EMA approval of datopotamab-deruxtecan: A paradigm shift in breast cancer drug evaluation?","volume":"84","author":"Orlandi","year":"2025","journal-title":"Breast"},{"key":"10.1016\/j.xcrm.2026.102934_bib15","doi-asserted-by":"crossref","first-page":"6942","DOI":"10.1097\/MS9.0000000000003857","article-title":"Datopotamab deruxtecan: a new era in targeted therapy for metastatic breast cancer","volume":"87","author":"Mobashir","year":"2025","journal-title":"Ann. Med. Surg."},{"key":"10.1016\/j.xcrm.2026.102934_bib16","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1634\/theoncologist.2011-S1-71","article-title":"Directed therapy of subtypes of triple-negative breast cancer","volume":"16","author":"Carey","year":"2011","journal-title":"Oncologist"},{"key":"10.1016\/j.xcrm.2026.102934_bib17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0231953","article-title":"Identification of triple-negative breast cancer cell lines classified under the same molecular subtype using different molecular characterization techniques: Implications for translational research","volume":"15","author":"Espinosa Fernandez","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.xcrm.2026.102934_bib18","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15041278","article-title":"Mechanisms of Resistance to Antibody-Drug Conjugates","volume":"15","author":"Abelman","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.xcrm.2026.102934_bib19","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1042\/BST20191055","article-title":"Targeted therapy and drug resistance in triple-negative breast cancer: the EGFR axis","volume":"48","author":"Lev","year":"2020","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.xcrm.2026.102934_bib20","doi-asserted-by":"crossref","first-page":"3848","DOI":"10.1158\/0008-5472.CAN-23-4099","article-title":"A Dual-Payload Antibody-Drug Conjugate Targeting CD276\/B7-H3 Elicits Cytotoxicity and Immune Activation in Triple-Negative Breast Cancer","volume":"84","author":"Zhou","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102934_bib21","doi-asserted-by":"crossref","DOI":"10.3390\/cells12192393","article-title":"A CD276-Targeted Antibody-Drug Conjugate to Treat Non-Small Lung Cancer (NSCLC)","volume":"12","author":"Zhang","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.xcrm.2026.102934_bib22","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s11307-021-01680-3","article-title":"Detection and Characterization of Sentinel Lymph Node by Ultrasound Molecular Imaging with B7-H3-Targeted Microbubbles in Orthotopic Breast Cancer Model in Mice","volume":"24","author":"Hu","year":"2022","journal-title":"Mol. Imag. Biol."},{"key":"10.1016\/j.xcrm.2026.102934_bib23","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1158\/0008-5472.CAN-14-3361","article-title":"Breast Cancer Detection by B7-H3-Targeted Ultrasound Molecular Imaging","volume":"75","author":"Bachawal","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102934_bib24","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s12943-023-01751-9","article-title":"New frontiers in immune checkpoint B7-H3 (CD276) research and drug development","volume":"22","author":"Getu","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.xcrm.2026.102934_bib25","doi-asserted-by":"crossref","first-page":"4062","DOI":"10.2174\/0929867326666190517115515","article-title":"B7-H3 Immune Checkpoint Protein in Human Cancer","volume":"27","author":"Flem-Karlsen","year":"2020","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.xcrm.2026.102934_bib26","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s13045-022-01364-7","article-title":"Immune checkpoint of B7-H3 in cancer: from immunology to clinical immunotherapy","volume":"15","author":"Zhao","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.xcrm.2026.102934_bib27","doi-asserted-by":"crossref","first-page":"4049","DOI":"10.1158\/0008-5472.CAN-24-0984","article-title":"mLumiOpto Is a Mitochondrial-Targeted Gene Therapy for Treating Cancer","volume":"84","author":"Chen","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102934_bib28","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.bpj.2019.06.038","article-title":"Precisely control mitochondria with light to manipulate cell fate decision","volume":"117","author":"Ernst","year":"2019","journal-title":"Biophys J."},{"key":"10.1016\/j.xcrm.2026.102934_bib29","doi-asserted-by":"crossref","DOI":"10.1186\/s13046-025-03572-8","article-title":"Combine mitochondrial-targeted gene therapy and chemotherapy to treat triple-negative breast cancer","volume":"44","author":"Varadkar","year":"2025","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102934_bib30","article-title":"Anti-lipolysis-stimulated lipoprotein receptor antibody-drug conjugate to treat triple-negative breast cancer","volume":"15","author":"Zhou","year":"2025","journal-title":"Front. Oncol."},{"key":"10.1016\/j.xcrm.2026.102934_bib31","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/s41417-020-0196-5","article-title":"Anti-SSTR2 Antibody-drug Conjugate for Neuroendocrine Tumor Therapy. Cancer Gene Therapy","volume":"28","author":"Si","year":"2020","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.xcrm.2026.102934_bib32","doi-asserted-by":"crossref","first-page":"130","DOI":"10.3390\/biomedicines10010130","article-title":"Targeted Extracellular Vesicles Delivered Verrucarin A to Treat Glioblastoma","volume":"10","author":"Chen","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.xcrm.2026.102934_bib33","doi-asserted-by":"crossref","first-page":"1900163","DOI":"10.1002\/biot.201900163","article-title":"Targeted Exosomes for Drug Delivery: Biomanufacturing, Surface Tagging, and Validation","volume":"15","author":"Si","year":"2020","journal-title":"Biotechnol. J."},{"key":"10.1016\/j.xcrm.2026.102934_bib34","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14010146","article-title":"Targeted EV to Deliver Chemotherapy to Treat Triple-Negative Breast Cancers","volume":"14","author":"Si","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.xcrm.2026.102934_bib35","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.3390\/pharmaceutics12111079","article-title":"Dual-Targeted Extracellular Vesicles to Facilitate Combined Therapies for Neuroendocrine Cancer Treatment","volume":"12","author":"Si","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.xcrm.2026.102934_bib36","doi-asserted-by":"crossref","first-page":"3749","DOI":"10.3390\/cancers13153749","article-title":"Targeted liposomal chemotherapies to treat triple-negative breast cancer","volume":"13","author":"Si","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.xcrm.2026.102934_bib37","doi-asserted-by":"crossref","first-page":"427","DOI":"10.3390\/ph14050427","article-title":"Antibody-Drug Conjugate to Treat Meningiomas","volume":"14","author":"Chen","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.xcrm.2026.102934_bib38","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/elsc.202000027","article-title":"Anti-EGFR antibody-drug conjugate for triple-negative breast cancer therapy","volume":"21","author":"Si","year":"2021","journal-title":"Eng. Life Sci."}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379126003514?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379126003514?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T00:22:30Z","timestamp":1793060550000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379126003514"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":38,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2666379126003514"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2026.102934","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combine antibody-drug conjugate with cmLumiOpto for triple-negative breast cancer treatment","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2026.102934","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102934"}}